AEOL 11114B / Aeolus - LARVOL DELTA

Aeolus Announces $6.75 Million Private Placement Financing (Yahoo Finance) - "Aeolus Pharmaceuticals, Inc...announced today that it has entered into definitive agreements with certain institutional and other accredited investors to raise gross proceeds of $6.75 million in a private placement financing....In addition, the Company intends to use the proceeds to pursue human clinical trials with AEOL 10150 in Idiopathic Pulmonary Fibrosis and radiation oncology and the completion of pre-clinical development of AEOL 20415 for infectious diseases and AEOL 11114B for Parkinson's disease."

Financing • CNS Disorders • Idiopathic Pulmonary Fibrosis • Parkinson's Disease • Pulmonary Disease

Optimization of lipophilic metalloporphyrins modifies disease outcomes in a rat model of parkinsonism. (PubMed, J Pharmacol Exp Ther) - "In this study, a pharmaceutical formulation of two metalloporphyrin catalytic antioxidants, AEOL11207 and AEOL11114 was tested for oral drug delivery. Both compounds significantly attenuated dopamine depletion, cytokine production, microglia activation, dopaminergic neuronal loss, oxidative/nitrative stress indices and behavioral abnormality in a Parkinson's disease rat model. The results suggest that both metalloporphyrins possess disease-modifying properties which may be useful in treating Parkinson's disease."

Journal • Preclinical • CNS Disorders • Gastrointestinal Disorder • Immunology • Inflammation • Movement Disorders • Parkinson's Disease